

# Claudio Agostinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4762834/publications.pdf>

Version: 2024-02-01

136  
papers

5,505  
citations

101535

36  
h-index

88628

70  
g-index

142  
all docs

142  
docs citations

142  
times ranked

7141  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.9	429
2	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	8.5	363
3	Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. <i>Journal of Clinical Oncology</i> , 2006, 24, 2472-2479.	1.6	354
4	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	4.4	323
5	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007, 117, 823-834.	8.2	272
6	Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation. <i>Cancer Research</i> , 2007, 67, 10703-10710.	0.9	220
7	Myeloid Sarcoma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 426-437.	0.7	198
8	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	7.0	189
9	Alteration of <i>BIRC3</i> and multiple other NF- $\kappa$ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	1.4	176
10	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	1.6	129
11	Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. <i>Blood</i> , 2011, 117, 3596-3608.	1.4	128
12	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. <i>Blood</i> , 2015, 125, 2530-2543.	1.4	125
13	Reproducing the molecular subclassification of peripheral T-cell lymphoma "NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	1.4	120
14	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, e81-e82.	3.5	117
15	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	10.7	100
16	IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. <i>Histopathology</i> , 2012, 61, 930-941.	2.9	99
17	Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing. <i>Journal of Biological Chemistry</i> , 2013, 288, 35534-35547.	3.4	80
18	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. <i>Haematologica</i> , 2008, 93, 1033-1038.	3.5	73

#	ARTICLE	IF	CITATIONS
19	Expression of CD52 in peripheral T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 566-567.	3.5	67
20	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	4.6	63
21	Primary Bone Marrow Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 296-304.	3.7	59
22	Expression of platelet-derived growth factor receptor $\beta$ in peripheral T-cell lymphoma not otherwise specified. <i>Lancet Oncology</i> , 2005, 6, 440.	10.7	58
23	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019, 104, 729-737.	3.5	58
24	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	1.8	58
25	Prevalence of <i>Chromobacter xylosoxidans</i> in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. <i>British Journal of Haematology</i> , 2014, 164, 804-810.	2.5	54
26	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. <i>Histopathology</i> , 2011, 59, 679-691.	2.9	51
27	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?. <i>Histopathology</i> , 2011, 59, 1173-1182.	2.9	47
28	Pathobiology of Hodgkin Lymphoma. <i>Advances in Hematology</i> , 2011, 2011, 1-18.	1.0	46
29	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.	1.8	44
30	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	3.8	43
31	Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. <i>Oncotarget</i> , 2017, 8, 16463-16472.	1.8	43
32	The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 35-47.	2.5	42
33	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolmunology</i> , 2019, 8, e1617588.	4.6	41
34	Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. <i>Journal of Infection</i> , 2006, 53, e243-e246.	3.3	38
35	Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 489-494.	1.2	38
36	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020, 33, 179-187.	5.5	37

#	ARTICLE	IF	CITATIONS
37	Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2009, 94, 285-288.	3.5	36
38	CD38, BCL2, PD1, and PD1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017, 92, E1-E2.	4.1	33
39	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. <i>Histopathology</i> , 2012, 61, 33-46.	2.9	32
40	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. <i>Histopathology</i> , 2013, 62, 860-875.	2.9	32
41	slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018, 78, 3544-3559.	0.9	31
42	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015, 6, 6544-6552.	1.8	31
43	Prognostic Markers in Peripheral T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 222-228.	2.3	30
44	Peripheral T-cell lymphoma classification: the matter of cellular derivation. <i>Expert Review of Hematology</i> , 2011, 4, 415-425.	2.2	30
45	Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. <i>Histopathology</i> , 2017, 71, 769-777.	2.9	29
46	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , 2010, 95, 2056-2062.	3.5	28
47	A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1345-1354.	5.5	28
48	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	17.0	28
49	Construction and validation of a bone marrow tissue microarray. <i>Journal of Clinical Pathology</i> , 2007, 60, 57-61.	2.0	24
50	Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 561-572.	1.2	24
51	GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. <i>BMC Cancer</i> , 2012, 12, 586.	2.6	24
52	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <i>Molecular Cancer Research</i> , 2017, 15, 541-552.	3.4	24
53	Novel markers in pediatric-type follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 771-779.	2.8	22
54	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.	3.3	22

#	ARTICLE	IF	CITATIONS
55	Lymphoma classification: the quiet after the storm. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 113-123.	1.5	20
56	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 575-582.	2.8	20
57	Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. <i>Rheumatology International</i> , 2012, 32, 2209-2213.	3.0	19
58	Intracellular TCR-signaling Pathway. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1349-1359.	3.7	19
59	CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. <i>Modern Pathology</i> , 2019, 32, 37-47.	5.5	19
60	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. <i>Modern Pathology</i> , 2019, 32, 1359-1372.	5.5	19
61	IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation. <i>Journal of Immunology Research</i> , 2015, 2015, 1-20.	2.2	18
62	Pathobiology of Anaplastic Large Cell Lymphoma. <i>Advances in Hematology</i> , 2010, 2010, 1-10.	1.0	17
63	Primary cutaneous lymphomas: a reprisal. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 214-233.	1.5	17
64	The Microenvironment's Role in Mycosis Fungoides and S�azary Syndrome: From Progression to Therapeutic Implications. <i>Cells</i> , 2021, 10, 2780.	4.1	17
65	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. <i>BMC Clinical Pathology</i> , 2009, 9, 11.	1.8	16
66	Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 218.	0.8	16
67	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castlemans disease. <i>European Journal of Cancer</i> , 2016, 64, 159-166.	2.8	16
68	Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 234-244.	1.5	15
69	Vascular endothelial growth factor A (<sc>VEGFA</sc>) expression in mycosis fungoides. <i>Histopathology</i> , 2015, 66, 173-181.	2.9	14
70	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. <i>Clinical Science</i> , 2020, 134, 1151-1166.	4.3	14
71	PATHOBIOLOGY OF HODGKIN LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014040.	1.3	13
72	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	1.7	13

#	ARTICLE	IF	CITATIONS
73	Photodynamic therapy: An option in mycosis fungoides. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 20, 107-110.	2.6	12
74	Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review. <i>Histopathology</i> , 2020, 77, 293-302.	2.9	12
75	Gene Expression Analysis of Follicular Lymphoma Provides a Potential Rationale for Histological Grading Revision.. <i>Blood</i> , 2007, 110, 186-186.	1.4	12
76	Biology and treatment of follicular lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 533-547.	2.2	11
77	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. <i>BMC Cancer</i> , 2018, 18, 645.	2.6	11
78	Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. <i>Haematologica</i> , 2009, 94, 1036-1037.	3.5	10
79	Pathobiology of ALK-negative anaplastic large cell lymphoma. <i>Mental Illness</i> , 2011, 3, 5.	0.8	10
80	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. <i>BMC Cancer</i> , 2014, 14, 396.	2.6	10
81	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 330-334.	2.5	10
82	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. <i>European Journal of Haematology</i> , 2021, 106, 737-739.	2.2	10
83	Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma. <i>Cancers</i> , 2021, 13, 3634.	3.7	10
84	Three-dimensional models: a novel approach for lymphoma research. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 753-765.	2.5	9
85	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. <i>British Journal of Haematology</i> , 2006, 134, 356-356.	2.5	8
86	Leukocytoclastic Vasculitis Associated with Hairy Cell Leukemia at Diagnosis: A Case Report and Review of the Literature. <i>Tumori</i> , 2016, 102, S124-S127.	1.1	8
87	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?. <i>European Journal of Dermatology</i> , 2017, 27, 49-53.	0.6	8
88	IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. <i>Apmis</i> , 2017, 125, 511-522.	2.0	8
89	Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. <i>Human Pathology</i> , 2017, 59, 94-101.	2.0	8
90	BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role. <i>Frontiers in Oncology</i> , 2020, 10, 662.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Burkitt lymphoma with a granulomatous reaction: an M1/Th1-polarised microenvironment is associated with controlled growth and spontaneous regression. <i>Histopathology</i> , 2022, 80, 430-442.	2.9	8
92	Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. <i>Hematological Oncology</i> , 2022, 40, 58-63.	1.7	8
93	Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2013, 2013, 1-13.	1.9	7
94	<i>BRAF</i> V600E mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. <i>British Journal of Haematology</i> , 2015, 170, 282-285.	2.5	7
95	The emerging role of GSK-3 $\beta$ in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , 2017, 71, 72-80.	2.9	7
96	Histopathology of B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 807-826.	2.2	6
97	Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. <i>Journal of Clinical Pathology</i> , 2006, 60, 581-582.	2.0	6
98	BCL10 down-regulation in peripheral T-cell lymphomas. <i>Human Pathology</i> , 2012, 43, 2266-2273.	2.0	6
99	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 749-757.	2.8	6
100	Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. <i>Human Pathology</i> , 2018, 81, 131-137.	2.0	6
101	Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 60.	0.8	5
102	Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 441-450.	2.8	5
103	Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. <i>Heliyon</i> , 2019, 5, e02643.	3.2	5
104	Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 961-968.	2.8	5
105	Primary uterine localization of malt lymphoma: A case report and literature review. <i>Leukemia Research</i> , 2011, 35, e185-e187.	0.8	4
106	Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e119-e122.	0.4	4
107	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	5.0	4
108	<i>BRAF</i> V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4807-4812.	2.0	4



#	ARTICLE	IF	CITATIONS
109	Intron 4 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance. <i>Endocrine Pathology</i> , 2021, 32, 385-395.	9.0	4
110	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. <i>Human Pathology</i> , 2022, 124, 67-75.	2.0	4
111	Follicular lymphoma: still Six characters in search of an author?. <i>Leukemia and Lymphoma</i> , 2011, 52, 1655-1667.	1.3	3
112	Plaques and tumors in a patient with refractory SÅžary syndrome treated with mogamulizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1263-1265.	0.8	3
113	Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition. <i>Blood</i> , 2013, 122, 2502-2502.	1.4	3
114	CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. <i>Journal of Clinical Pathology</i> , 2011, 64, 83-87.	2.0	2
115	The role of myeloid derived suppressor cells in mycosis fungoides. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1175-1176.	4.2	2
116	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 99-102.	0.8	2
117	Lymph node core needle biopsy in lymphoproliferative disorders Authors reply to AlÅbbadi and colleagues. <i>European Journal of Haematology</i> , 2021, 107, 297-298.	2.2	2
118	Alopecia areata-like mycosis fungoides: lions for lambs. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 293-295.	0.2	2
119	Paediatric follicular lymphoma. <i>Diagnostic Histopathology</i> , 2016, 22, 6-10.	0.4	1
120	Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existence of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.. <i>Blood</i> , 2005, 106, 1217-1217.	1.4	1
121	Verrucous mycosis fungoides. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 504-505.	0.8	1
122	Granulomatous tattoo reaction in a nivolumab-treated patient. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 530-532.	0.8	1
123	SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity reply. <i>Human Pathology</i> , 2017, 66, 238-239.	2.0	0
124	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma Authors reply. <i>Lancet Haematology,the</i> , 2017, 4, e64-e66.	4.6	0
125	Cytotoxic EpsteinÅBarr virus positive large B cell lymphoma: a regulatory B cell derived neoplasia?. <i>Histopathology</i> , 2017, 70, 650-656.	2.9	0
126	How can we better predict treatment outcomes in classical Hodgkin's lymphoma?. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 65-68.	1.6	0



#	ARTICLE	IF	CITATIONS
127	A large mass and erythematousâ€œviolaceous plaques. JDDG - Journal of the German Society of Dermatology, 2018, 16, 372-375.	0.8	0
128	RALE051: a novel established cell line of sporadic Burkitt lymphoma. Leukemia and Lymphoma, 2018, 59, 1252-1255.	1.3	0
129	Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review. Bariatric Surgical Patient Care, 2018, 13, 90-93.	0.5	0
130	Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.. Blood, 2005, 106, 2819-2819.	1.4	0
131	Bone Marrow in Hodgkin Lymphoma and Mimickers. , 2012, , 237-252.		0
132	Signaling Pathways in Rare Lymphomas. , 2014, , 71-95.		0
133	Extramedullary metastatic plasmacytoma in multiple myeloma. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 741-743.	0.8	0
134	SÃ©zary Syndrome without erythroderma featuring a CD30+ progression. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 494-495.	0.8	0
135	Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. Italian Journal of Dermatology and Venereology, 2019, , .	0.2	0
136	PD-1 and PD-L1 expression in mycosis fungoides and SÃ©zary Syndrome. Italian Journal of Dermatology and Venereology, 2022, , .	0.2	0